Pharmacy Medical News about cervical cancer

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Statins and cancer risk

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Evaluation of the paclitaxel–ifosfamide–cisplatin (TIP) combination in relapsed and/or metastatic cervical cancer
British Journal of Cancer, 09/16/09

Kosmas C et al. – Recurrent or metastatic cervical cancer represents an aggressive malignancy with a high rate of locoregional and distant failure. TIP is an active regimen with acceptable toxicity in advanced/relapsed cervical cancer.

Exclusive Author Commentary
C Kosmas, 09/16/09

The Paclitaxel-Ifosfamide-Cisplatin (TIP) regimen appears to be active and relatively tolerable, except some slightly excessive (approx. 20%) rate of febrile neutropenic episodes, which are rapidly reversible mostly with home antibiotic therapy (amoxicillin/clavulanate+ciproxin). The regimen has shown to be highly active in patients with relapses outside previously irradiated pelvic sites, in particular lymph nodes and pulmonary metastases. Moreover, about 15% of patients with para-aortic lymph node metastases have experienced >2-year survival.

<< Previous
Pamidronate-Induced Kidney Injury in a Patient With Metastatic...

Next >>
U.S. FDA Licenses Sanofi Pasteurs Pandemic Influenza Vaccine